Medical Representative detailing to a doctor.
[MR should never become the financial shock absorber for an unrealistic target.]
For 38 years, I watched the pharmaceutical industry from the field. I saw the Medical Representative evolve from a traditional product messenger into a professional expected to understand doctors, patients, competition and business.
But the MR’s world in 2026 is becoming much tougher.
Doctors have less time. Competition is intense. Companies expect faster growth. Distributors are under pressure. Targets keep rising. And, increasingly, the MR is caught between the expectations of the company and the realities of the market.
This is the part of the pharmaceutical business we need to discuss honestly.
Doctors Still Need Medical Representatives
The relationship between doctors and MRs is not disappearing. It is changing.
Doctors still value representatives who bring relevant clinical information, new product developments and reliable evidence. But the old approach of repeatedly presenting the same brand message is losing effectiveness.
Today’s doctor expects an MR to be:
- Scientifically knowledgeable
- Brief and relevant
- Honest about the product
- Respectful of time
- Capable of answering difficult questions
The Uniform Code of Pharmaceutical Marketing Practices (UCPMP) 2024 also places greater emphasis on ethical, transparent and responsible interaction between pharmaceutical companies and healthcare professionals.
The message is clear: credibility has become more important than promotional noise.
The Bigger Problem Is Happening Behind the Doctor’s Door
The difficult reality for many MRs is not simply gaining doctor access.
It is achieving the sales number after leaving the clinic.
India’s pharmaceutical market is currently showing an interesting contradiction. August 2026 recorded 10.7% value growth to ₹23,272 crore, while unit-volume growth was only around 1%. Recent Pharmarack data reported by Business Standard shows that price increases and new launches are contributing substantially to the industry’s growth.
That distinction is extremely important for the field force.
A growing market does not automatically mean that every territory is growing naturally.
When Targets Become More Important Than Real Demand
This is where the pressure begins.
An MR may be asked to achieve a particular monthly primary-sales target. The distributor or stockist may already have sufficient inventory. Yet the company still expects the number to be achieved.
That can create pressure for additional purchases even when genuine secondary movement is not keeping pace.
The result can be a dangerous chain:
Company target → distributor pressure → inventory loading → MR pressure → personal financial stress.
There are also field-level accounts of MRs being pushed to contribute money from their own pockets when sales numbers fall short. This is not something that should be treated as a normal cost of employment.
If an employee has to use personal money simply to make a company sales figure appear satisfactory, the question is no longer about salesmanship.
It is about the sustainability of the sales system.
The Distributor Is Also Under Pressure
This problem cannot be viewed only from the MR’s side.
The distributor has inventory, credit commitments, margins, expiry risks and working-capital requirements. The latest industry discussion around August 2026 pharma performance has itself highlighted the importance of sustainable trade margins, healthy inventory movement and reasonable credit terms.
That should make everyone stop and think.
A sale to the distributor is not necessarily the same thing as genuine market demand.
If products move from the company warehouse to the distributor but remain on the distributor’s shelf, the problem has merely moved one step forward.
Why the MR Profession Is Losing Some of Its Attraction
The MR profession once offered young people a clear career path, independence and the satisfaction of building relationships.
Today, many field employees face another reality: relentless targets, reporting requirements, travel, doctor-access problems, distributor pressure and intense competition.
At the same time, the industry continues to recruit heavily. One August 2026 pharma hiring report recorded 3,494 pharmaceutical sales vacancies, with Medical Representatives accounting for more than half of the listed roles.
So the paradox is obvious:
The industry still needs MRs, but it must make the profession worth staying in.
What Should Pharma Companies Change?
The answer is not to eliminate targets.
Targets are necessary in any business.
But targets should be connected to genuine market potential rather than artificial month-end numbers.
Companies should measure:
- Sustainable secondary sales
- Territory growth
- Doctor engagement quality
- Distributor inventory health
- Customer retention
- Ethical execution
- Long-term brand development
Most importantly, an MR should never become the financial shock absorber for an unrealistic target.
My View After 38 Years in Pharma Sales
I still believe strongly in the Medical Representative profession.
A good MR can educate, communicate, build trust and create genuine business value. But the profession cannot survive on pressure alone.
The industry needs to understand that a distributor is not merely a billing point, a doctor is not merely a prescription source, and an MR is not merely a number attached to a territory.
All three are human parts of the same healthcare ecosystem.
The future MR will need stronger scientific knowledge, digital skills, ethical discipline and commercial understanding.
But pharmaceutical companies have an equally important responsibility: give their field force realistic targets, healthy distribution practices and a working environment where success does not require personal financial sacrifice.
The Real Takeaway
Indian doctors are becoming more selective. Distributors are becoming more cautious. Competition is becoming tougher. And MRs are carrying pressure from every direction.
The pharmaceutical industry may be growing strongly in value, but the quality and sustainability of that growth deserve equal attention.
For me, the real question in 2026 is not whether Medical Representatives will survive.
They will.
The question is whether the industry will create an MR profession that talented young people still want to join—and experienced professionals still feel proud to continue.
That is the reality pharma cannot afford to ignore.
#RavisPerspective #MedicalRepresentatives #PharmaIndia #PharmaSales #MRProfession